Intellia gets FDA clearance to start hereditary angioedema gene editing trial in US
Intellia Therapeutics announced Thursday morning that the FDA cleared it to test a gene editing therapy for hereditary angioedema (HAE) in clinical trials in the US. The Cambridge, MA biotech is already running the trial in New Zealand, the Netherlands, and the UK.
Intellia’s HAE treatment, known as NTLA-2002, is the first in vivo gene editing treatment delivered by lipid nanoparticles to get cleared by the FDA for human trials. Lipid nanoparticles, or LNPs, are tiny balls of fatty acids that were used as delivery vehicles in the mRNA Covid vaccines.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
